CNTB CONNECT BIOPHARMA HLDGS LTD

Connect Biopharma to Present at the San Francisco Biotech Showcase in January

Connect Biopharma to Present at the San Francisco Biotech Showcase in January

SAN DIEGO and TAICANG, SUZHOU, China, Dec. 19, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that Zheng Wei, PhD, Co-Founder and CEO of Connect Biopharma will present a corporate update on January 9, at 9:00 am PST, during the upcoming Biotech Showcase taking place in person January 9 – 11, 2023.

Connect Biopharma’s senior leadership team, including Chief Financial Officer, Steven Chan and Chief Medical Officer, Chin Lee, MD, MPH will also be available for meetings with potential investors and partners in San Francisco during the Biotech Showcase / JP Morgan Healthcare Conference week.

Meetings can be requested through the  or by contacting Connect Biopharma at .

About Connect Biopharma Holdings Limited

Connect Biopharma is a U.S. and China-based clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases through the development of therapies derived from T cell research. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis and asthma. The Company’s second most advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis. The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with atopic dermatitis.

#BiotechShowcase

INVESTOR CONTACT:

Ina McGuinness

805.427.1372

MEDIA

Deanne Eagle

917.837.5866





EN
19/12/2022

Underlying

CNTBCONNECT BIOPHARMA HLDGS LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONNECT BIOPHARMA HLDGS LTD

 PRESS RELEASE
Free
CNTB CONNECT BIOPHAR...

Connect Biopharma Presents Data Supporting Rademikibart at the Europea...

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025 – Rademikibart demonstrated rapid and significant improvement in lung function and asthma control in patients, with greatest improvements observed in those with elevated baseline levels of key type 2 inflammatory markers – – Significant reduction in annualized exacerbations observed in patients with one or more elevated type 2 inflammatory markers at baseline – – Data supports ongoing Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to repo...

September 29, 2025 1 EN
 PRESS RELEASE
Free
CNTB CONNECT BIOPHAR...

Connect Biopharma Announces Two Presentations at the European Respirat...

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025 SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced two poster presentations at the European Respiratory Society (ERS) Congress 2025, taking place September 27 – October 1, 2025, in Amsterdam, Netherlands and virtually. The presentation details are as follows: Abstract ...

September 4, 2025 1 EN
 PRESS RELEASE
Free
CNTB CONNECT BIOPHAR...

Connect Biopharma Completes Termination of its American Depositary Rec...

Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it has completed the termination of the Deposit Agreement dated March 18, 2021, as amended, among the Company, Deutsche Bank Trust Company Americas, and the holders and beneficial owners of ...

September 3, 2025 1 EN
 PRESS RELEASE
Free
CNTB CONNECT BIOPHAR...

Connect Biopharma to Present at Two Upcoming Investor Conferences in S...

Connect Biopharma to Present at Two Upcoming Investor Conferences in September SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in the following upcoming conferences: Cantor Global Healthcare Conference 2025Format: Fireside ChatDate: Wednesday, September 3rd, 2025Time: 3:20 p.m. ETWebcast Link: H.C. Wainwright 27th Annual Glob...

August 27, 2025 1 EN
 PRESS RELEASE
Free
CNTB CONNECT BIOPHAR...

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundat...

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide Company and Former Cincinnati Bengals Running Back Known for the “Ickey Shuffle” Collaborate to Raise Awareness and Drive Asthma Education with Focus on Acute Attacks SAN DIEGO and CINCINNATI, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company) and the (the Foundation) today kicked off a collaboration to expand the Foundation’s asthma education program across the U.S. On this day in 2010, ...

August 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch